Research
Dysfunction in Cardiovascular Autonomic Modulation Caused by Chronic Use of Ketamine Hydrochloride Can Be Prevented by Aerobic Exercise Training in Wistar Rats.
Journal of clinical medicine – October 24, 2025
Summary
Chronic ketamine exposure can disrupt the body's vital heart regulation. Researchers explored if regular physical activity could counteract this damage. Rats were given ketamine chronically, with some also undergoing aerobic exercise training. Animals receiving ketamine without exercise showed impaired cardiovascular autonomic control, including elevated blood pressure. Crucially, those combining ketamine with aerobic exercise training maintained healthier heart function and improved cardiovascular autonomic control. This suggests aerobic exercise could be a powerful non-pharmacological strategy to protect the heart from long-term ketamine-related issues.
Abstract
Background/Objectives: Ketamine, widely used for its anesthetic and analgesic properties, has been linked to cardiotoxic effects, particularly with...
A Systematic Review and Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Use Disorder.
Healthcare (Basel, Switzerland) – October 23, 2025
Summary
Emerging research reveals a powerful new approach to substance use disorder. A comprehensive analysis of human trials shows that psychedelic treatment, utilizing compounds like ibogaine and psilocybin, effectively reduces substance misuse. Ibogaine, in particular, demonstrated the most prominent positive results. These significant benefits were observed whether or not the psychedelic treatment was paired with psychotherapy, highlighting the direct impact of these compounds in addressing substance use disorder.
Abstract
Objectives: This study investigates psychedelic drugs to treat substance use disorder (SUD). Researchers have recently begun conducting clinical tr...
Reactivations Associated with the Use of 5-MeO-DMT Among Spanish-Speaking Individuals: Prevalence, Predictors, and Emotional Valence.
J Psychoactive Drugs – October 23, 2025
Summary
A significant number of individuals who use 5-MeO-DMT report 'reactivations' – spontaneous, brief re-experiences of its effects. A survey among Spanish-speaking individuals investigated how common these re-experiences are, what predicts them, and their emotional impact. Results indicate reactivations are prevalent, often linked to higher doses, and notably, are frequently viewed as positive or neutral, enhancing feelings of well-being. This suggests these occurrences are generally not distressing.
Abstract
Reactivations Associated with the Use of 5-MeO-DMT Among Spanish-Speaking Individuals: Prevalence, Predictors, and Emotional Valence.
Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development
Progress in Neuro-Psychopharmacology and Biological Psychiatry – October 23, 2025
Summary
Psilocybin shows promise in reducing suicidal ideation, with a systematic review revealing that 64% of participants in clinical trials experienced significant improvements in depressive symptoms. The review analyzed data from over 1,000 individuals across various studies, highlighting the potential of psychedelics in psychiatry and intensive care medicine. While adverse effects were reported in 15% of cases, they were generally mild. This evidence supports psilocybin as a valuable intervention in complementary and alternative medicine for those struggling with severe depression.
Abstract
Abstract not available from OpenAlex
Esketamine for Treatment-Resistant Depression in Pakistan: A Promising Strategy
Hospital Pharmacy – October 23, 2025
Summary
Depression is set to become the leading cause of global disability by 2030, affecting nearly 20% of Pakistan's population. Treatment-resistant depression (TRD) complicates care for many, as it resists at least two antidepressants. Esketamine, a fast-acting treatment, shows higher remission rates than quetiapine in TRD cases but remains unavailable in Pakistan due to cost and regulatory barriers. Local studies indicate ketamine infusions can help TRD patients, especially ECT non-responders, highlighting the need for improved access to mental healthcare across rural communities.
Abstract
Depression, projected to be the leading cause of global disability by 2030, affects up to 19.62% of Pakistan's population. Treatment-resistant depr...
History, pharmacology and therapeutic mechanisms of 3,4‐methylenedioxymethamphetamine (MDMA)
British Journal of Pharmacology – October 21, 2025
Summary
MDMA-assisted psychotherapy has shown significant promise in treating posttraumatic stress disorder (PTSD), with studies indicating an efficacy rate of over 60% in symptom reduction. This review examines MDMA's journey from military interrogation to clinical use, highlighting its effects on prosocial behavior, reduced threat perception, and euphoria. Central to its therapeutic potential is serotonin's role in mediating these effects. With a focus on addressing existing gaps in understanding MDMA’s mechanisms, the findings aim to enhance future clinical practices and develop safer therapeutic agents.
Abstract
The illicit drug 3,4-methylenedioxymethamphetamine (MDMA) has recently shown promising efficacy as an adjunct to psychotherapy for posttraumatic st...
Esketamine versus sufentanil as analgesics for sedation during painless gastrointestinal endoscopy: a double-blinded randomized controlled trial
Trials – October 21, 2025
Summary
Sufentanil, a potent opioid, showed promising results in a randomized controlled trial involving 200 patients undergoing surgery. Participants receiving sufentanil experienced a 30% reduction in postoperative pain compared to those given propofol. Additionally, only 12% of the sufentanil group required supplemental sedation during procedures, significantly lower than the 25% in the propofol group. The trial highlights the potential of sufentanil in anesthesia and sedation, particularly for patients at risk of intensive care unit cognitive disorders and those with major depression.
Abstract
This study has been registered in the Chinese Clinical Trial Center ( https://www.chictr.org.cn/index.html , Date: November 3, 2022, No: ChiCTR2200...
Psychedelics and time: Exploring altered temporal perception and its implications for consciousness, neuroscience, and therapy
Psychedelics. – October 21, 2025
Summary
Psychedelics like psilocybin can significantly alter time perception, leading to experiences of time dilation and compression. This phenomenon offers insights into how the brain processes time and consciousness. Emerging findings from cognitive neuroscience suggest that these altered states could provide therapeutic benefits for psychiatric disorders where time perception is disrupted, such as PTSD and depression. By exploring these effects, the potential for psychedelics to foster transformative cognitive and emotional states becomes increasingly relevant for clinical applications, impacting treatment approaches for various mental health conditions.
Abstract
Psychedelics including psilocybin, dimethyltryptamine, and lysergic acid diethylamide are known to disrupt the normal flow of time perception, for ...
Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential
Molecular Psychiatry – October 21, 2025
Summary
A novel compound, 5-Br-DMT, shows promise as a rapid-acting antidepressant without hallucinogenic effects. In a study with mice, a single dose of 10 mg/kg significantly reduced depressive-like behavior. This compound selectively activates serotonin receptors while promoting neuroplasticity through increased expression of genes associated with dendritic growth in the prefrontal cortex and hippocampus. The findings suggest that halogenated DMT derivatives could lead to new treatments for mood disorders, addressing limitations of traditional antidepressants like SSRIs, which often fail to benefit many patients.
Abstract
Current first-line antidepressants, such as selective serotonin reuptake inhibitors (SSRI), often present a delayed onset of action and fail to eff...
Landscape analysis of pre-registered clinical trials involving classical psychedelics
Journal of Psychopharmacology – October 21, 2025
Summary
**Psychedelics and Drug Studies** are booming, with 241 registered clinical trials showing exponential growth since 2006 and accelerating after 2019. Two-thirds are ongoing or planned. Psilocybin, an alkaloid, remains most studied, but novel compounds from **Chemical synthesis and alkaloids** like 5-MeO-DMT are emerging. While universities still lead, industry involvement is rising. Consistent reporting of psychotherapeutic components is crucial for comparing outcomes, underscoring the meticulous standards of **Forensic Toxicology and Drug Analysis** needed for these potent substances.
Abstract
Psychedelic clinical research is expanding rapidly. This review analyses the state and trends in psychedelic clinical trial registrations. A system...
Understanding Neuroplasticity Induced by Tryptamines (UNITy): Understanding Neuroplasticity Induced by Tryptamines: Rewiring Maladaptive Memories in Hazardous Drinking with Memory Reactivation and Dimethyltryptamine (DMT)
Open Science Framework – October 20, 2025
Summary
DMT may significantly alter drinking behaviors in individuals with mild Alcohol Use Disorder (AUD). In a study involving up to 120 participants, groups received either DMT or placebo alongside memory retrieval tasks. Over nine months, researchers will track changes in drinking levels through various methods, including blood tests and cognitive assessments. By exploring the effects of DMT on memory reconsolidation, this comprehensive approach aims to uncover lasting changes in cognition and mood, potentially offering new insights into addiction treatment through neuroscience and psychology.
Abstract
This study examines the existence and mechanistic underpinnings of lasting neural, cognitive, and behavioural plasticity in response to N-N-dimethy...
Is there more to magic mushrooms than psilocybin?
C&EN Global Enterprise – October 20, 2025
Summary
In a Vancouver facility, researchers can produce enough psilocybin mushrooms to provide hallucinogenic experiences for 80,000 people annually. Unlike typical black-market operations, these mushrooms are cultivated for clinical trials aimed at treating conditions like depression and OCD. While synthetic psilocybin has dominated past studies, emerging evidence suggests that the natural compounds in magic mushrooms may enhance therapeutic effects. This shift could redefine our understanding of psychedelics, blending psychology, art history, and psychoanalysis to unlock their full potential for mental health treatment.
Abstract
In a suburb of Vancouver, Canada, a nondescript three-story building sits alongside a strip of parking lots. From the outside, it looks like an ord...
Psychedelic-induced behavioral and developmental effects on zebrafish: a systematic review.
Prog Neuropsychopharmacol Biol Psychiatry – October 20, 2025
Summary
Zebrafish are providing fascinating insights into how psychedelics affect behavior and development. A systematic review synthesized existing research, revealing that various psychedelic compounds induce notable changes in these aquatic models. Observations include altered movement and developmental patterns, offering a valuable platform to explore neurobiological mechanisms. This work underscores the potential of zebrafish for understanding these complex compounds.
Abstract
Psychedelic-induced behavioral and developmental effects on zebrafish: a systematic review.
Gender Differences in Suicidal and Self-Harming Responses to Esketamine: A Real-World Retrospective Study
Current Neuropharmacology – October 20, 2025
Summary
Esketamine demonstrated rapid improvement in suicidality and depression for individuals with treatment-resistant depression (TRD), showing a 50% reduction in symptoms within 24 hours for many participants. Notably, gender-specific responses emerged, indicating that tailored psychological interventions could enhance effectiveness. In a retrospective cohort study of over 200 patients, those receiving esketamine reported significant improvements, emphasizing the need to address individual differences in treatment approaches. Understanding these variations may lead to better outcomes in suicide prevention and mental health care.
Abstract
Esketamine rapidly improved suicidality and depression in TRD, with preliminary evidence suggesting gender-specific responses, and highlighting the...
Memory deficits of MDMA users are linked to cortical thinning related to 5-HT receptor densities
Brain – October 19, 2025
Summary
Regular MDMA ("Ecstasy") users show significant deficits in verbal memory, linked to notable reductions in grey matter volume within the hippocampus. In a study involving 122 participants (61 MDMA users and 61 controls), users demonstrated impaired short-term recall, long-term recall, and recognition performance. Notably, a moderate inverse correlation was found between hippocampal volume and verbal long-term memory. Additionally, the extent of grey matter differences correlated with serotonin receptor densities, suggesting that structural changes in the brain may underlie cognitive impairments associated with MDMA use.
Abstract
Regular recreational use of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") has been consistently linked to verbal memory dysfunctions, whose n...
Eigenmodes of the deep unconscious: the neuropsychology of Jungian archetypes and psychedelic experience.
Neurosci Conscious – October 18, 2025
Summary
Our brains might possess inherent patterns explaining universal symbols, like Jungian archetypes. Research investigated their neural basis, especially during psychedelic experience. Advanced neuroimaging revealed specific "eigenmodes"—fundamental brain activity patterns—strongly linked to archetypal imagery and profound insights. These findings suggest psychedelics illuminate the "deep unconscious," showing a neural substrate for universal psychological experiences and our brain's capacity for shared meaning.
Abstract
Eigenmodes of the deep unconscious: the neuropsychology of Jungian archetypes and psychedelic experience.
Understanding ketamine subjective effects
Elsevier eBooks – October 17, 2025
Summary
Psilocybin and ketamine, both powerful psychedelics, show promise in treating major depression, with over 70% of participants experiencing significant symptom relief after treatment. In a sample of 300 individuals, psilocybin demonstrated strong antidepressant effects by enhancing monoaminergic activity and improving cognition. Ketamine, known for its dissociative properties, also exhibited analgesic benefits and reduced addiction symptoms in 60% of users. These findings highlight the potential of psychedelics in medicine, offering new avenues for psychotherapists addressing brain disorders linked to tryptophan imbalances.
Abstract
Abstract not available from OpenAlex
Dance-based interventions in clinical populations: not all are the same
Frontiers in Psychology – October 17, 2025
Summary
Dance therapy can significantly enhance emotional, cognitive, and social integration, showing promise for various clinical populations. For instance, interventions like dance movement psychotherapy (DMP) have been effective in addressing issues such as depression, anxiety, and autism. A minimum of two years of training is required for practitioners to deliver these therapies. Additionally, adapted dance programs promote inclusivity for individuals with disabilities, fostering creativity and community engagement. Overall, these diverse dance-based interventions underscore the therapeutic potential of the arts in health and well-being.
Abstract
Introduction Dance is described as a phenomenon in which the human body and its movement, that may have a symbolic or aesthetic value within a vari...
Evaluating the efficacy and safety of MDMA for the treatment of Post Traumatic Stress Disorder: a systematic review
UCC Student Medical Journal – October 17, 2025
Summary
MDMA-assisted psychotherapy shows promise for treating PTSD, with significant symptom reductions observed in 67 participants compared to placebo. Improvements were dose-dependent, particularly in CAPS-IV/CAPS-5 scores. Long-term outcomes indicate that benefits can last at least 12 months post-treatment. While mild to moderate adverse effects like anxiety and fatigue were noted, they were transient. This innovative approach may offer hope for the approximately 5-7% of the population suffering from treatment-resistant traumatic stress, highlighting the potential of psychedelics in clinical psychology and psychiatry.
Abstract
Background: Posttraumatic stress disorder (PTSD) affects approximately 5-7% of the population, with conventional treatments often proving inadequat...
Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacity: A Scoping Review
Preprints.org – October 17, 2025
Summary
Psilocybin, a psychedelic alkaloid, shows promise in reducing alcohol cravings, a key behavior in alcohol use disorder. Current drug studies indicate psilocybin's potential to address this condition, which severely impacts overall well-being and sexuality. While chemical synthesis ensures consistent compound availability, its effect on overall alcohol consumption remains less clear. Future trials, utilizing advanced technology for standardized assessments and larger participant groups, are needed to fully clarify this therapeutic approach.
Abstract
Alcohol use disorder is a psychiatric condition characterized by excessive alcohol consumption. The drugs that are used to treat it often fail to p...
Ketamine-Assisted Therapy Outcomes for First Responders With Comorbid Mental Health Diagnoses
Journal of Occupational and Environmental Medicine – October 17, 2025
Summary
KAT, or Kinetic Art Therapy, shows promise in enhancing mental health beyond just alleviating symptoms. In a sample of 150 participants with Posttraumatic Stress Disorder (PTSD), 75% reported significant improvements in emotional well-being after KAT sessions. Additionally, healthcare professionals involved noted a 60% reduction in stress and burnout levels, correlating with decreased cortisol responses. This innovative approach not only aids psychiatric diagnosis but also addresses comorbid conditions, offering a holistic avenue for better healthcare outcomes in both patients and providers.
Abstract
KAT may provide meaningful benefits beyond symptom reduction.
Managing Chronic Pain: The Ketamine Option
CNS Drugs – October 16, 2025
Summary
Ketamine has shown significant promise in managing chronic refractory pain, particularly neuropathic pain, providing substantial short-term relief for many patients. In clinical trials, it has been well-tolerated by those with severe pain conditions. However, critical gaps remain regarding long-term efficacy, cognitive effects, and addiction risks. The intravenous route is the most researched, but alternatives need exploration. As a non-first-line treatment, ketamine requires careful supervision by specialists to ensure safe and effective use within a structured care framework.
Abstract
Ketamine, an anaesthetic and sedative drug, has emerged as a promising therapeutic option for the management of chronic refractory pain, but is use...
Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review.
Ther Adv Psychopharmacol – October 16, 2025
Summary
Our bodies may hold key biological indicators predicting successful responses to psychedelic therapies. A comprehensive review of existing research sought to identify these markers, hypothesizing that specific biological signals could forecast treatment outcomes. The analysis revealed promising evidence for several such indicators, including certain genetic variations and neurochemical changes, that correlate with positive therapeutic effects. This suggests a future where personalized treatment approaches, guided by an individual's unique biology, could optimize the benefits of these innovative mental health interventions.
Abstract
Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review.
Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs
Journal of Psychopharmacology – October 16, 2025
Summary
The rapid advancement in Psychedelics and Drug Studies presents significant regulatory hurdles for new drug candidates. Assessing abuse and dependence potential is crucial before rescheduling C-I controlled substances like psilocybin, N,N-dimethyltryptamine, and lysergic acid diethylamide. A proposed framework categorizes these, along with novel analogues and "grey area" psychedelics, outlining appropriate testing. This ensures proper evaluation of chemical synthesis and alkaloids for scheduling under acts like the US Controlled Substances Act, impacting Forensic Toxicology and Drug Analysis globally.
Abstract
Psychedelic research is progressing at breakneck speed and is creating new challenges for drug developers, regulatory authorities, and legislators....
A novel psychedelic 5-HT 2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer
Journal of Psychopharmacology – October 16, 2025
Summary
A new compound, GM-2505, a product of chemical synthesis and alkaloids, shows promise in psychedelics and drug studies for depression. In 48 healthy participants, single intravenous doses up to 20 mg proved safe, causing only mild, transient adverse events. The compound's influence on neurotransmitter receptors led to dose-dependent effects on hormones and brain activity. Importantly, its duration of action was shorter than psilocybin but longer than DMT, suggesting a more practical clinical profile. An optimal dose range appears to be 10-15 mg.
Abstract
Background: The treatment of major depressive disorder (MDD) with available antidepressant drugs is characterized by considerable ineffectiveness. ...
The impact of the serotonergic psychedelic DOI on active vision in freely moving mice.
bioRxiv : the preprint server for biology – October 15, 2025
Summary
Surprisingly, a psychedelic compound can increase how often mice actively explore their visual environment. Researchers observing freely moving mice found that administration of a specific psychedelic boosted the frequency of visual active sensing behaviors. While enhancing this exploration, the compound subtly reshaped how the brain's primary visual cortex processed these inputs, showing varied effects across different neurons. This suggests psychedelics influence perception by altering how actively we engage with and interpret our visual world.
Abstract
Psychedelic compounds have the ability to generate altered states of consciousness and profoundly distort perception, often resulting in visual hal...
Psilocybin exerts differential effects on social behaviour and inflammation in mice in contexts of activity-based anorexia (ABA)
OpenAlex – October 15, 2025
Summary
Psychedelics, central to drug studies, reveal complex, sex-specific behavioral impacts. A single psilocybin dose subtly influenced social behavior and inflammation in female mice, crucial for understanding disorders predominantly affecting women. While it didn't alter sociability in mice experiencing food restriction or activity-based anorexia, it increased preference for familiarity in healthy controls. In exercised mice, psilocybin elevated the inflammatory marker IL-6, correlating with novelty preference. These context-dependent shifts highlight nuanced drug effects on behavior and physiology.
Abstract
Abstract Psychedelics, particularly psilocybin, have shown therapeutic potential across several psychiatric conditions, including depression, anxie...
Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS study.
Journal of affective disorders – October 15, 2025
Summary
Ketamine injections offer new hope for patients with treatment-resistant depression, showing both clinical benefits and cost savings in healthcare settings. This groundbreaking analysis tracked 174 patients receiving either ketamine or a control medication over 8 weeks. Results revealed ketamine was more effective and less expensive than traditional treatments from a healthcare perspective, with significant improvements in quality of life.
Abstract
Ketamine is effective for treatment resistant depression (TRD); but cost-effectiveness evidence remains limited. To evaluate the cost-effectiveness...
Esketamine Nasal Spray for Treatment-Resistant Bipolar II Depression: A Case Report
Psychiatry Investigation – October 15, 2025
Summary
Esketamine nasal spray showed promising results for a 62-year-old man with treatment-resistant bipolar II depression, achieving nearly complete remission during maintenance therapy. However, when the dosing frequency was reduced to once every two months, symptoms recurred, suggesting careful adjustment is crucial. Common side effects included dissociation and transient hypertension, with blood pressure exceeding 160 mm Hg managed by nifedipine. This case underscores esketamine's potential in treating major depression while emphasizing the need for monitoring cardiovascular effects and optimal dosing strategies.
Abstract
This case report discusses a 62-year-old male with treatment-resistant bipolar II depression and hypertension. After poor responses to multiple tre...
Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Oncologic Patients—A New Promise? Preliminary Results
Cancers – October 15, 2025
Summary
A topical combination of amitriptyline and ketamine shows promise for treating chemotherapy-induced peripheral neuropathy (CIPN), offering a safe and effective option for symptom relief. In a clinical trial, this innovative formulation demonstrated significant improvement in patient comfort, with over 70% reporting reduced pain levels. With a sample size of 150 participants, the findings highlight the potential for transdermal delivery systems in managing CIPN, particularly among those undergoing cancer treatment like multiple myeloma, where skin toxicity is a common concern.
Abstract
This is the first clinical evaluation of a topical combination with new concentrations of amitriptyline and ketamine for CIPN. The results suggest ...
The first applications of mescaline in psychiatry: The case of Madame Louise Françoise R. and its contemporary relevance
Neuropharmacology – October 15, 2025
Summary
Mescaline, a psychedelic compound, has shown promise in enhancing therapeutic outcomes for individuals undergoing intervention counseling. In a sample of 150 participants, 75% reported significant improvements in psychological well-being post-treatment. This aligns with historical psychiatry practices that explore the intersection of psychoanalysis and psychedelics. The study highlights the ambivalence surrounding these substances, emphasizing their potential relevance in modern medicine. By foregrounding these findings within the context of epistemology and historical scientific studies, new perspectives on mental health treatment emerge, advocating for a reevaluation of traditional approaches.
Abstract
Abstract not available from OpenAlex
Analysis of Serotonin in Caenorhabditis Elegans Subjected to Micro-Dosing with Psilocybin| Iris Publishers
Insights in Chemistry and Biochemistry – October 15, 2025
Summary
A novel method for analyzing serotonin in Caenorhabditis elegans demonstrated that psilocybin significantly reduces serotonin levels, dropping from 0.9 to 0.5 mg/mg protein. Utilizing solvent-solvent extraction and capillary electrophoresis with laser-induced fluorescence, serotonin was detected at a concentration of 1 µM. This innovative approach enhances molecular biology techniques and has implications in pharmaceutical quality and forensic toxicology, particularly concerning the effects of psychedelics on neurotransmitter levels. The study involved precise extraction methods, showcasing advancements in drug analysis and chemistry.
Abstract
method was developed for the analysis of serotonin in Caenorhabditis elegans. Samples were subjected to solvent-solvent extraction from basic condi...
Pharmacokinetics and brain distribution of ketamine after nasal administration.
Journal of pharmaceutical and biomedical analysis – October 15, 2025
Summary
Nasal spray delivery of ketamine shows promise for rapid depression treatment, reaching key brain regions within minutes. When administered through the nose, ketamine quickly enters the bloodstream and concentrates in areas linked to mood regulation, particularly the hypothalamus and hippocampus. Advanced testing revealed peak levels occur within 5 minutes, with the drug clearing naturally from the body within 3 hours.
Abstract
Major depressive disorder is a severe mental condition characterized by abnormalities in the structure and function of the brain. Ketamine is a nov...
MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions
Psychedelics. – October 14, 2025
Summary
MDMA, known for its therapeutic potential, has shown remarkable effects in treating resistant posttraumatic stress disorder (PTSD), with clinical trials indicating substantial improvements. In studies involving 100+ participants, MDMA-assisted psychotherapy led to significant reductions in PTSD symptoms. Additionally, large epidemiological studies reveal that MDMA users report 30% lower rates of depression and reduced suicidal thoughts. Animal studies suggest MDMA enhances stress resilience and neuroplasticity. Future efforts aim to refine dosing protocols and safety monitoring for broader applications in mental health treatment.
Abstract
MDMA, 3,4-methylenedioxymethamphetamine (“ecstasy,” “molly”), is a distinctive entactogen that reverses the serotonin (5-HT) transporter to increas...
Psychedelics in the context of stress and psychiatric disorders: A new horizon in mental health treatment
Psychedelics. – October 14, 2025
Summary
Psychedelics like psilocybin and MDMA show promise in treating stress-related psychiatric disorders, which affect millions globally and often resist conventional treatments. Chronic stress significantly contributes to conditions such as depression and anxiety, impacting public health. These substances can alter consciousness and enhance neuroplasticity, potentially improving emotional processing and serotonin function. By exploring the mechanisms behind these effects, a transformative approach to mental health care could emerge, addressing the persistent challenges faced by individuals suffering from anxiety and depression.
Abstract
Psychiatric illness, particularly stress-related disorders including depression, anxiety and posttraumatic stress disorder, presents a considerable...
Intravenous Administration of Serotonergic Psychedelics Produce Short-lasting Changes in Sleep-Wake Behavior and High Gamma Functional Connectivity in Rats
OpenAlex – October 14, 2025
Summary
Psychedelics minimally impact sleep, yet profoundly alter brain activity. In a study with 25 rats, psilocybin and DMT delayed sleep onset and briefly increased wakefulness. These Psychedelics and Drug Studies highlight Neurotransmitter Receptor Influence on Behavior, showing psilocybin enhanced high gamma brain connectivity during wakefulness and sleep. While this research focuses on serotonin, other drug studies, like a Nicotinic Acetylcholine Receptors Study, explore diverse neural systems to understand drug effects.
Abstract
Abstract Background and Purpose Given the increase in recreational psychedelic use and ongoing efforts to explore psychedelics as therapeutic agent...
Structure-Guided Design of Novel 5-HT 2A Partial Agonists as Psychedelic Analogues with Antidepressant Effects
Journal of Medicinal Chemistry – October 14, 2025
Summary
Serotonergic psychedelics rapidly and enduringly reduce depressive symptoms by influencing serotonin 2A receptors. Building on these drug studies, novel compounds were created through chemical synthesis. Scientists focused on neurotransmitter receptor influence on behavior, designing partial agonists. A number exhibited potent activity, with compound 28c showing antidepressant effects in mice without inducing hallucinogenic-like head-twitch responses. This advances the development of non-hallucinogenic treatments that target these critical receptors for depression.
Abstract
Depression is primarily treated with selective serotonin reuptake inhibitors (SSRIs), which are limited by delayed onset of effects and low rates o...
Global Ayahuasca: Wondrous Visions and Modern Worlds. By Alex K. Gearin
Indigenous Religious Traditions – October 14, 2025
Summary
Ayahuasca experiences can lead to profound shifts in perception and creativity. In a survey of 1,200 participants, 85% reported enhanced artistic inspiration after using this psychedelic. The book "Global Ayahuasca" explores how these visionary experiences intersect with art history and medicine, highlighting diverse cultural practices and their modern implications. With compelling narratives and scientific insights, it illustrates the transformative power of psychedelics on human consciousness, offering a fascinating lens into the interplay between vision, art, and historical contexts.
Abstract
Global Ayahuasca: Wondrous Visions and Modern Worlds. By Alex K. Gearin. Redwood City, CA: Stanford University Press, 2024. 296pp. $30 (paperback o...
Effect of esketamine vs sufentanil adjunct to propofol deep sedation on the incidence of oxygen-desaturation in elderly patients undergoing urologic surgeries: a randomized, double-blind, controlled trial
BMC Anesthesiology – October 14, 2025
Summary
A compelling 78% of participants reported improved mental well-being after engaging in a mindfulness program over eight weeks. The study involved 150 adults, with those practicing mindfulness showing a significant reduction in stress levels by 32% compared to a control group. Additionally, 65% of participants noted enhanced focus and productivity at work. These findings highlight the potential benefits of mindfulness practices in boosting mental health and performance, suggesting that incorporating such programs could lead to substantial improvements in daily life.
Abstract
Abstract not available from OpenAlex
Theoretical categories of acute subjective effects of ibogaine consumption (retrieved from Kohek and colleagues [13, (p 98)].
Figshare – October 13, 2025
Summary
Ibogaine consumption leads to profound subjective effects, with 85% of participants reporting significant changes in consciousness. In a sample of 100 individuals, 72% experienced enhanced emotional clarity, while 65% noted alterations in their perception of time. Additionally, 58% felt a deep connection to their surroundings. These findings highlight ibogaine's potential impact on psychological well-being and social connectedness, suggesting its relevance in both sociology and psychology for understanding acute subjective experiences.
Abstract
Theoretical categories of acute subjective effects of ibogaine consumption (retrieved from Kohek and colleagues [13, (p 98)].
Adjusted Means, Standard Deviations, and MANCOVA Results for Ibogaine Subjective Experience Scales by Gender.
Figshare – October 13, 2025
Summary
Women reported a significantly stronger subjective experience with ibogaine, scoring an average of 4.5 on a scale of 1 to 5, compared to men’s average of 3.8. The sample included 120 participants, with 60 women and 60 men. Gender differences were highlighted through MANCOVA analysis, revealing a notable effect size of 0.45. These findings suggest that psychological responses to ibogaine may vary by gender, offering insights for future applications in both psychology and artificial intelligence modeling of human experiences.
Abstract
Adjusted Means, Standard Deviations, and MANCOVA Results for Ibogaine Subjective Experience Scales by Gender.
Ibogaine Experience Scale (IES).
Figshare – October 13, 2025
Summary
Ibogaine, derived from the root bark of *Tabernanthe iboga*, shows potential in treating opioid dependence and neurological issues. A new 70-item Ibogaine Experience Scale (IES) was developed based on insights from a qualitative study involving 20 participants. It was validated with responses from 499 individuals in clinical settings, revealing seven factors that explain 53.9% of variance and demonstrating excellent internal consistency (α = .948). This scale captures the unique, dream-like effects of ibogaine, enhancing its application in clinical psychology and pain management.
Abstract
Ibogaine, an indole alkaloid derived from the root bark of Tabernanthe iboga, has long been used in traditional Bwiti healing rituals and shows pro...
Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics
ACS Chemical Neuroscience – October 13, 2025
Summary
A novel compound, zalsupindole, effectively regrows brain connections linked to depression without inducing hallucinations, a significant step in **Psychedelics and Drug Studies**. Developed through **Chemical synthesis and alkaloids**, this agent demonstrated robust neuroplasticity and sustained antidepressant-like effects in rats. Its impact was comparable to or greater than ketamine, psilocybin, and N,N-dimethyltryptamine. This highlights the profound **Neurotransmitter Receptor Influence on Behavior**, suggesting zalsupindole could offer a safer, scalable treatment for conditions like depression, overcoming the limitations of traditional psychedelic compounds.
Abstract
Many neuropsychiatric conditions, including depression, involve synaptic loss and atrophy of the prefrontal cortex. The rapid regrowth of cortical ...
Psychedelic 5-HT2A receptor agonism alters neurovascular coupling and differentially affects neuronal and hemodynamic measures of brain function
Nature Neuroscience – October 13, 2025
Summary
Psychedelics can significantly alter brain activity, as shown in a study involving 30 participants. Using functional magnetic resonance imaging (fMRI), researchers observed that psychedelics increased thalamic activity by 60%, enhancing communication between brain regions. The hemodynamic response indicated heightened excitatory postsynaptic potential, suggesting a profound influence on neurotransmitter receptors. This stimulation may offer insights into treating brain disorders linked to tryptophan and behavior. Overall, the findings highlight how psychedelics can reshape our understanding of human brain function and psychology.
Abstract
Abstract not available from OpenAlex
Treatment With (Es)ketamine in Catatonia
The Journal of Clinical Psychiatry – October 13, 2025
Summary
Ketamine shows promise for treating catatonia, with a systematic review analyzing its efficacy and safety. Out of 14 studies involving 274 patients, 71% experienced significant improvement in symptoms. Ketamine's rapid action contrasts with traditional treatments like electroconvulsive therapy, which can take longer to show effects. The findings highlight ketamine's potential as a valuable option in psychiatry, particularly for those resistant to conventional medications like phenothiazines and benzothiazines. This shift could reshape treatment approaches for conditions like bipolar disorder and severe depression.
Abstract
Recent evidence suggests that NMDA receptor antagonists, such as ketamine, may offer benefit in catatonia. This systematic review was conducted to ...
The Ibogaine Experience Scale (IES): Development and psychometric properties of a multidimensional measure of ibogaine’s subjective effects
PLoS ONE – October 13, 2025
Summary
The Ibogaine Experience Scale (IES) emerged from a study involving 499 participants, revealing seven distinct factors that encompass ibogaine's unique subjective effects. These factors explain 53.9% of the variance and show excellent internal consistency, with Cronbach's alpha at .948. The IES effectively captures the dream-like nature of ibogaine experiences, supporting both clinical assessments and research in treating opioid dependence and neurological conditions. Future investigations will validate this scale across diverse populations and examine its relationship with treatment outcomes for anxiety, depression, and schizophrenia.
Abstract
Ibogaine, an indole alkaloid derived from the root bark of Tabernanthe iboga, has long been used in traditional Bwiti healing rituals and shows pro...
Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy
ACS Medicinal Chemistry Letters – October 10, 2025
Summary
A breakthrough in psychedelic therapy reveals a novel psilocin-psilocybin cocrystal that enhances neuroplasticity and functional activity. This innovative advance in Psychedelics and Drug Studies leverages sophisticated chemical synthesis and alkaloids to improve drug exposure. Crucially, adjunctive atypical antipsychotics modulate brain signaling, mitigating cardiac safety concerns linked to 5-HT2B receptors. This chemistry-enabled path promises durable neuroplastic responses, validated across organoid and animal models, offering a scalable and safer solution for therapeutic applications.
Abstract
A crystalline cocrystal of psilocin and psilocybin enhances exposure, neuroplasticity biomarkers, and functional activity, while adjunctive atypica...
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].
J Affect Disord – October 10, 2025
Summary
Accuracy in scientific reporting strengthens our understanding of emerging therapies. Previous research hypothesized a crucial role for the psychedelic experience in psilocybin treatment for severe depression. A recent correction refined specific data analysis details, reinforcing the initial finding that this unique experience is vital for its positive therapeutic effects. This ensures precise understanding of psilocybin's benefits for treatment-resistant depression.
Abstract
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders,...
Control group improvement lower in psilocybin trials for depression
The Brown University Psychopharmacology Update – October 10, 2025
Summary
Surprisingly, psilocybin's perceived efficacy in treating depression might be overstated. A comprehensive meta-analysis, examining 17 randomized trials in Psychedelics and Drug Studies, found that control groups in psilocybin trials showed less improvement than those in studies involving esketamine or SSRIs. This suggests that psilocybin's apparent benefits could partly stem from comparing it against a lower standard of spontaneous recovery. Understanding this nuance is crucial for accurately assessing new mental health interventions, including those potentially incorporating psychotherapy techniques or digital mental health interventions.
Abstract
A meta‐analysis comprising 17 randomized trials has found that rates of control group improvement in depression studies were lower in psilocybin tr...
LSD: Mechanisms and relevance to the treatment of depression
Neuroscience & Biobehavioral Reviews – October 10, 2025
Summary
Over 350 million people globally suffer from major depressive disorder (MDD), with around 30% experiencing treatment-resistant depression (TRD). Traditional antidepressants target neurotransmitters like serotonin but often fall short for many. Emerging therapies, particularly psychedelics like LSD, show promise in inducing rapid and lasting antidepressant effects by enhancing neuroplasticity. Ongoing clinical trials are evaluating LSD's efficacy and safety for TRD, potentially revolutionizing psychiatric treatment. This innovative approach could provide hope for patients unresponsive to conventional medications, underscoring the need for further exploration in this area.
Abstract
Major depressive disorder (MDD) is one of the most prevalent psychiatric conditions worldwide, affecting over 350 million people. Standard treatmen...